Apogee Therapeutics
Develops long-acting antibody therapies for atopic dermatitis, asthma, and other inflammatory diseases.
Something off on this page? Send us feedback.
Profile
Develops long-acting antibodies for atopic dermatitis and respiratory diseases, led by zumilokibart and combination programs APG279 and APG273. With no approved products or program revenue, operations depend on clinical and regulatory progress; a shareholder-approved acquisition by AbbVie remains pending.
Develops engineered, long-acting antibodies for inflammatory and immunological diseases, with atopic dermatitis and respiratory disorders at the center of a U.S.-based clinical portfolio. Zumilokibart, an IL-13 antibody, has completed mid-stage testing in atopic dermatitis and is being prepared for late-stage trials; expansion studies are planned in asthma and eosinophilic esophagitis. APG279 combines zumilokibart with an OX40L antibody for atopic dermatitis, while APG273 combines IL-13 and TSLP blockade for asthma and COPD.
Builds around validated immune targets while using antibody engineering to pursue less frequent dosing and combining complementary pathways. No product is approved and no program revenue has been generated, leaving operations dependent on clinical outcomes, regulatory approval, and outsourced manufacturing. A shareholder-approved acquisition by AbbVie remains subject to other closing conditions.
Company facts
Key statistics
Year to date +78.1% · Average volume (30d) 1.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Truist Financial | Target | $81 | $135 | ||
| Aug 12, 2026 | BTIG | Downgrade | Buy | Neutral | ||
| Jun 24, 2026 | Stifel Nicolaus | Target | $133 | $135 | ||
| Jun 24, 2026 | Mizuho Securities | Target | $135 | |||
| Jun 24, 2026 | TD Cowen | Downgrade | Buy | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$1.07 | −$1.14 | −6.5% | $10.0M | $816.0K | −91.8% | −0.14% |
| May 11, 2026Q1 FY26 | −$1.12 | −$1.06 | +5.4% | — | — | — | −1.97% |
| Mar 2, 2026Q4 FY25 | −$1.05 | −$1.03 | +1.9% | — | — | — | −3.41% |
| Nov 10, 2025Q3 FY25 | −$1.12 | −$1.11 | +0.9% | — | — | — | +10.89% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | −$400.0K | $400.0K | −$408.0K | $0 | |
| Operating income | −$63.1M | −$73.2M | −$71.3M | −$78.1M | −$82.8M | −$96.0M | |
| Net income | −$55.3M | −$66.1M | −$65.0M | −$69.4M | −$74.1M | −$85.9M | |
| Diluted EPS | −$0.95 | −$1.13 | −$1.11 | −$1.03 | −$1.06 | −$1.14 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $971.9M · Total debt $6.8M · Total assets $1.34B · Shareholders' equity $1.19B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 61.88M · Float 57.17M · 92.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| VR Adviser, LLC | 8.49M | 13.73% | 13F | Aug 14, 2026 |
| Tomas Kiselak | 6.81M | 9.99% | 13D | Jun 23, 2026 |
| BlackRock, Inc. | 5.51M | 8.90% | 13F | Aug 7, 2026 |
| Wellington Management Group LLP | 4.75M | 8.70% | 13G | Feb 10, 2026 |
| HBK Investments L P | 2.85M | 4.61% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 5, 2026 | Carl Dambkowski | officer: Chief Medical Officer | −5,500 | $134.17 |
| Jul 8, 2026 | Michael Thomas Henderson | director, officer: Chief Executive Officer | −20,000 | $133.63 |
| Jul 1, 2026 | Carl Dambkowski | officer: Chief Medical Officer | −5,500 | $132.74 |
| Jun 22, 2026 | Michael Thomas Henderson | director, officer: Chief Executive Officer | −80,000 | $132.54 |
| Jun 22, 2026 | Carl Dambkowski | officer: Chief Medical Officer | −26,400 | $132.60 |
Peers
- Regeneron
IL-4Rα/IL-13 bispecific DUPIXENT leads AD; 9 approved indications worldwide.
- Sanofi (ADR)
DUPIXENT commercializer and amlitelimab (anti-OX40L) filing for AD in H2 2026.
- Eli Lilly
Approved IL-13 inhibitor Ebglyss; same target, same indication as zumilokibart.
- AbbVie
Leading oral JAK1 inhibitor RINVOQ competes in moderate-to-severe AD.
- AstraZeneca (ADR)
Global biopharma holding the only approved anti-TSLP biologic, Tezspire.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Apogee Therapeutics | $135.02 | +0.04% | $8.35B | — | — | — | — |
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Median | 39.4 | 16.0 | 5.3 | +11.2% |